Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 20:10:325-331.
doi: 10.2147/ITT.S255722. eCollection 2021.

B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20

Michael Levy  1 , Maureen A Mealy  2
Affiliations
Review

B-Cell Targeted Treatments for Neuromyelitis Optica Spectrum Disorder: A Focus on CD19 and CD20

Michael Levy et al. Immunotargets Ther. .

Abstract

Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing autoimmune disease of the central nervous system that preferentially targets the optic nerves and spinal cord, leading to visual loss and impaired mobility. Until 2019, no medications were FDA-approved for NMOSD treatment, and standard of care was based on mostly empiric and retrospective data. Therapies that target B cells emerged as a treatment strategy due to their fundamental role in disease pathogenesis. We explore different monoclonal antibodies directed at either CD20+ or CD19+ B cells that may have utilization in the treatment of NMOSD, discussing what is known regarding their efficacy and safety.

Keywords: MOG; NMO; inebilizumab; monoclonal; rituximab.

PubMed Disclaimer

Conflict of interest statement

Michael Levy has received consulting income from Horizon Therapeutics (manufacturer of inebilizumab), Genentech (manufacturer of rituximab), Alexion, UCB Pharmaceuticals and Mitsubishi Pharmaceuticals. He has also received grants from these companies funding research at Massachusetts General Hospital. Maureen A. Mealy works for Horizon Therapeutics, the manufacturer of inebilizumab. Her contribution to the manuscript herein does not necessarily represent the views of Horizon Therapeutics. The authors report no other potential conflicts of interest for this work.

Figures

Figure 1
Figure 1
B cells migrate from from the peripheral circulation to the central nervous system after they are activated in lymph nodes. AQP4 antibodies are mostly produced by peripheral AQP4-reactive B cells but during a relapse, some plasmablasts make AQP4 antibody within the CNS.
See this image and copyright information in PMC

References

    1. Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch Neurol. 2012;69(9):1176–1180. doi:10.1001/archneurol.2012.314 - DOI - PubMed
    1. Levy M, Wildemann B, Jarius S, et al. Immunopathogenesis of neuromyelitis optica. Adv Immunol. 2014;121:213–242. doi:10.1016/B978-0-12-800100-4.00006-4 - DOI - PubMed
    1. Kowarik MC, Astling D, Gasperi C, et al. CNS aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder. Ann Clin Transl Neurol. 2017;4(6):369–380. eCollection 2017 Jun. doi:10.1002/acn3.418 - DOI - PMC - PubMed
    1. Mealy MA, Mossburg SE, Kim SH, et al. Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions. Mult Scler Relat Disord. 2019;28:64–68. Epub 2018 Dec 9. doi:10.1016/j.msard.2018.12.011 - DOI - PMC - PubMed
    1. Kessler RA, Mealy MA, Levy M. Treatment of neuromyelitis optica spectrum disorder: acute, preventive, and symptomatic. Neurol Neuroimmunol Neuroinflamm. 2018;5(4):e468. eCollection 2018 Jul. doi:10.1212/NXI.0000000000000468 - DOI - PMC - PubMed

LinkOut - more resources